The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
PD-1 Blockade in Anaplastic Thyroid Carcinoma
Open accessAbstract
PURPOSE: Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with BRAF-wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor. METHODS: We enrolled patients with locally advanced and/or metastatic anaplastic thyroid carcinoma in a phase II cohort of the study. Patients received 400 mg spartalizumab intravenously, once every 4 weeks. The overall response rate was determined according to RECIST v1.1. RESULTS: Forty-two patients were enrolled. Adverse events were consistent with those previously observed with PD-1 blockade. Most common treatment-related adverse events were diarrhea (12%), pruritus (12%), fatigue (7%), and pyrexia (7%). The overall response rate was 19%, including three patients with a complete response and five with a partial response. Most patients had baseline tumor biopsies positive for PD-L1 expression (n = 28/40 evaluable), and response rates were higher in PD-L1–positive (8/28; 29%) versus PD-L1–negative (0/12; 0%) patients. The highest rate of response was observed in the subset of patients with PD-L1 ≥ 50% (6/17; 35%). Responses were seen in both BRAF-nonmutant and BRAF-mutant patients and were durable, with a 1-year survival of 52.1% in the PD-L1–positive population. CONCLUSION: To our knowledge, this is the first clinical trial to show responsiveness of anaplastic thyroid carcinoma to PD-1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“21 A subset of these neoantigens are immunogenic and provide targets for recognition by the immune system and disease control.”
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“…were also analyzed by next-generation sequencing (Foundation Medicine, Cambridge, Massachusetts) to assess mutations affecting cancer-related genes and tumor mutation burden, 17 and by RNA sequencing (RNAseq) to evaluate gene expression patterns, including interferon gamma (IFN γ ) signature.”
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 911
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Maleki Vareki, S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0479-7 · Cited by 569
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Pozdeyev, N., Gay, L. M., Sokol, E. S., Hartmaier, R., Deaver, K. E., Davis, S., French, J. D., Borre, P. V., LaBarbera, D. V., Tan, A.-C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0373 · Cited by 533
Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
Smallridge, R. C., & Copland, J. A. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.03.013 · Cited by 481
Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing
Kunstman, J. W., Juhlin, C. C., Goh, G., Brown, T. C., Stenman, A., Healy, J. M., Rubinstein, J. C., Choi, M., Kiss, N., Nelson-Williams, C., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu749 · Cited by 364
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
Haddad, R. I., Nasr, C., Bischoff, L., Busaidy, N. L., Byrd, D., Callender, G., Dickson, P., Duh, Q.-Y., Ehya, H., Goldner, W., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0089 · Cited by 356
Self-citationKaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0310-x · Cited by 334
Iyer, P. C., Dadu, R., Gule-Monroe, M., Busaidy, N. L., Ferrarotto, R., Habra, M. A., Zafereo, M., Williams, M. D., Gunn, G. B., Grosu, H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0378-y · Cited by 239
Cancer of the microsatellite mutator phenotype.
Perucho, M. (1996) · PubMed · Cited by 227
Khoja, L., Butler, M. O., Kang, S. P., Ebbinghaus, S., & Joshua, A. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0078-9 · Cited by 225
Self-citationNivolumab: Targeting PD-1 to Bolster Antitumor Immunity
Brahmer, J. R., Hammers, H., & Lipson, E. J. (2015) · Future Oncology · doi:10.2217/fon.15.52 · Cited by 199
Comprehensive screening for PD-L1 expression in thyroid cancer
Ahn, S., Kim, T. H., Kim, S. W., Ki, C. S., Jang, H. W., Kim, J. S., Kim, J. H., Choe, J.-H., Shin, J. H., Hahn, S. Y., et al. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-16-0421 · Cited by 173
Khunger, M., Hernández, A. V., Pasupuleti, V., Rakshit, S., Pennell, N. A., Stevenson, J. P., Mukhopadhyay, S., Schalper, K. A., & Velcheti, V. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00030 · Cited by 159
Anaplastic thyroid carcinoma: review of treatment protocols
Tiedje, V., Stuschke, M., Weber, F., Dralle, H., Moss, L., & Führer, D. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0435 · Cited by 114
Self-citationNaing, A., Gainor, J. F., Gelderblom, H. A. J., Forde, P. M., Butler, M. O., Lin, C., Sharma, S., de Olza, M. O., Varga, A., Taylor, M. H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000530 · Cited by 89
Self-citationExceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
Kollipara, R., Schneider, B. P., Radovich, M., Babu, S., & Kiel, P. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0096 · Cited by 78
CD 70 and PD ‐L1 in anaplastic thyroid cancer – promising targets for immunotherapy
Zwaenepoel, K., Jacobs, J., Meulenaere, A. D., Silence, K., Smits, E., Siozopoulou, V., Hauben, E. I., Rolfo, C. D., Rottey, S., & Pauwels, P. (2017) · Histopathology · doi:10.1111/his.13230 · Cited by 68
Cited by
Bible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0944 · Cited by 730
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Haddad, R. I., Bischoff, L., Ball, D., Bernet, V., Blomain, E., Busaidy, N. L., Campbell, M., Dickson, P., Duh, Q.-Y., Ehya, H., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0040 · Cited by 510
Self-citationCurigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, D., Forde, P. M., Sarantopoulos, J., Bedard, P. L., Lin, C.-C., Hodi, F. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4746 · Cited by 362
Self-citationSubbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C. C., Cabanillas, M. E., Boran, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2021.12.014 · Cited by 357
Shonka, D. C., Ho, A., Chintakuntlawar, A. V., Geiger, J. L., Park, J. C., Seetharamu, N., Jasim, S., Abdelhamid Ahmed, A. H., Bible, K. C., Brose, M. S., et al. (2022) · Head & Neck · doi:10.1002/hed.27025 · Cited by 117
Self-citation
Metadata
- Authors
- Capdevila, J., Wirth, L. J., Ernst, T., Ponce Aix, S., Lin, C.-C., Ramlau, R., Butler, M. O., Delord, J.-P., Gelderblom, H., Ascierto, P. A., Fasolo, A., Führer, D., Hütter-Krönke, M. L., Forde, P. M., Wrona, A., Santoro, A., Sadow, P. M., Szpakowski, S., Wu, H., Bostel, G., Faris, J., Cameron, S., Varga, A., & Taylor, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-08-10
- Volume
- 38
- Issue
- 23
- Pages
- 2620-2627
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3021719484
- Cited by
- 353
- References
- 26
- FWCI
- 29.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.